Essra Ridha, MD, MRCP, FFPM
Chief Medical Officer
Essra is a global medical leader with extensive experience in clinical research and development, translational medicine, and clinical medicine with specialist training in cardiology and internal medicine.
Essra’s experience includes strategically and scientifically advancing the ex vivo lentiviral gene therapy now licensed for the treatment of metachromatic leukodystrophy (MLD) and the first CAR-T regulatory cell therapy to enter the clinic for the induction of immunological tolerance in solid organ transplantation. She has worked in leadership positions within AVROBIO as well as Sangamo Therapeutics and GlaxoSmithKline, on highly innovative cell and gene therapy programs in rare neurological, metabolic (including lysosomal disorders) and immunological diseases. Previously, Dr. Ridha worked as a medical expert at Bristol Myers Squibb advising on late-stage clinical development, medical affairs, real-world evidence and HEOR in cardiovascular medicine.
In addition to her industry leadership, Essra is a member of the Royal College of Physicians of London, as well as a Fellow of the Faculty of Pharmaceutical Medicine. She was also an expert panel member at the World Health Organization (WHO) Expert Advisory Committee to develop Global Standards for the Governance and Oversight of Human Genome Editing. She earned her medical degrees from the Royal Free and University College London Medical School and earned her neuroscience degree with Basic Medical Sciences degree with honors from University College London.